October 2019

UROLOGY

MOLECULAR MARKERS OFFER OPPORTUNITIES TO IMPROVE UNDERSTANDING OF THE BIOLOGY AND TREATMENT OF BLADDER CANCER

Featuring: Joshua J. Meeks, MD, PhD

Episode Summary

In the United States, there are an estimated 72,570 new cases of bladder cancer each year. The Northwestern Medicine Department of Urology evaluates and manages each patient with emphasis on an integrated, multidisciplinary and stage-specific approach. Our team is committed to conducting innovative research to increase our understanding of the biology of bladder cancer and identifying new therapies and technologies for bladder cancer in order to improve quality of life for our patients.

In this episode of the Better Edge podcast, Joshua J. Meeks, MD, PhD, assistant professor of Urology and a member of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, joins the show to share how his team of scientists are involved in three active trials focused on genetic and epigenetic changes in bladder cancer, as well as immuno-oncology in bladder cancer. 
Joshua J. Meeks, MD, PhD, assistant professor in the Divisions of Urology and Biochemistry and Molecular Genetics at Northwestern Medicine. 

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like